Sign In
Buy BSX
$47.69
+0.0100 (+0.0210%)
At Close: Jun 03, 2026
Why Boston Scientific (BSX) Might Surprise This Earnings Season
09:47am, Tuesday, 27'th Apr 2021
Boston Scientific (BSX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Medical Product Stocks' Earnings on Apr 28: BSX, ALGN & More
09:47am, Tuesday, 27'th Apr 2021
The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.
Boston Scientific's (BSX) Watchman US Sale to Aid Q1 Earnings
09:01am, Friday, 23'rd Apr 2021
Within Boston Scientific's (BSX) coronary therapies, drug-eluting stents sale continue to be a challenge from a pricing standpoint in Q1.
Boston Scientific (BSX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
01:32pm, Wednesday, 21'st Apr 2021
Boston Scientific (BSX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Boston Scientific: Set To Climb 27%, Options Offer An Even Bigger Return
12:02pm, Tuesday, 20'th Apr 2021
Recent price action indicates that BSX could reach $52. An equity research firm just initiated coverage with a price target of $52.
Boston Scientific Corp (BSX) EVP&Pres, Periph Intervent Jeffrey B. Mirviss Sold $1.
08:15pm, Friday, 16'th Apr 2021
EVP&Pres, Periph Intervent of Boston Scientific Corp (30-Year Financial, Insider Trades) Jeffrey B. Mirviss (insider trades) sold 28,123 shares of BSX on 04/15/2021 at an average price of $40.95 a sha
Final Trades: Northrop Grumman, Boston Scientific, Nvidia & more
02:21pm, Thursday, 15'th Apr 2021
The "Halftime Report" traders give their top picks to watch for the second half.
AMD, Boston Scientific, Intel, Nvidia and More Thursday Afternoon Analyst Calls
12:11pm, Thursday, 15'th Apr 2021
With the trading day about halfway over, the broad markets were pushing much higher with solid gains across the board.
Late-Breaking Data Supports Boston Scientific's (BSX) TheraSphere
04:07pm, Tuesday, 30'th Mar 2021
Boston Scientific's (BSX) TheraSphere is expected to be used as a safe and effective treatment option for numerous HCC patients worldwide on the back of positive trial results.
MARLBOROUGH, Mass., March 26, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarte
Boston Scientific (BSX) Hurt by Product Recall, Currency Woes
09:06am, Friday, 26'th Mar 2021
Boston Scientific (BSX) currently expects its 2021 organic revenues to include a headwind of $62 million from 2020 LOTUS Edge sales.
BioCardia Is Super Cheap With Multiple Shots On Goal
01:57pm, Thursday, 25'th Mar 2021
BioCardia Is Super Cheap With Multiple Shots On Goal
Late-Breaking Clinical Trial Data for TheraSphere™ Y-90 Glass Microspheres Demonstrates Improved Survival in Primary Liver Cancer
11:07am, Thursday, 25'th Mar 2021
MARLBOROUGH, Mass., March 25, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced positive data from the TARGET study of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere)
Boston Scientific's (BSX) TheraSphere Approved by FDA for HCC
01:37pm, Monday, 22'nd Mar 2021
Boston Scientific's (BSX) TheraSphere therapy to be made accessible to more patients following the FDA's clearance.
Boston Scientific Receives FDA Approval for TheraSphere™ Y-90 Glass Microspheres
07:00am, Thursday, 18'th Mar 2021
MARLBOROUGH, Mass., March 18, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the TheraSphere™ Y-90 Glas
